Microgenics keeps technology in management buy-out
This article was originally published in Clinica
Microgenics is buying itself out of Roche Boehringer Mannheim, taking with it the intellectual property rights to the technology it developed before the company was sold, first to Boehringer, and subsequently, in the Boehringer deal, to Roche.
You may also be interested in...
Accord Healthcare is looking to breaking into the crowded market for biosimilar trastuzumab in the EU, after partner Henlius’ application was backed by the EMA’s CHMP. Meanwhile, a recommendation for a generic to the Eliquis anticoagulant was also forthcoming from the committee.
The European Medicines Agency has provided an update on the status of its review of Gilead’s investigational antiviral in the treatment of COVID-19.
Sandoz has published the results of two studies involving the company’s pegfilgrastim biosimilar and glatiramer acetate generic. For the former, Sandoz observed cost savings could run eventually to tens of millions of dollars per year with patient conversion and expanded access.